 Proprotein Convertases
"Proprotein Convertases" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Proteolytic enzymes that are involved in the conversion of protein precursors such as peptide prohormones into PEPTIDE HORMONES. Some are ENDOPEPTIDASES, some are EXOPEPTIDASES.
| Descriptor ID |
D043484
|
| MeSH Number(s) |
D08.811.277.656.837
|
| Concept/Terms |
Proprotein Convertases- Proprotein Convertases
- Convertases, Proprotein
- Proprotein Convertase
- Convertase, Proprotein
Prohormone Convertases- Prohormone Convertases
- Convertases, Prohormone
- Prohormone Convertase
- Convertase, Prohormone
Subtilisin-Like Proprotein Convertases- Subtilisin-Like Proprotein Convertases
- Convertases, Subtilisin-Like Proprotein
- Proprotein Convertases, Subtilisin-Like
- Subtilisin Like Proprotein Convertases
Pro-Opiomelanocortin Converting Enzyme- Pro-Opiomelanocortin Converting Enzyme
- Converting Enzyme, Pro-Opiomelanocortin
- Pro Opiomelanocortin Converting Enzyme
- POMC Enzyme
- POMC-Converting Enzyme
- POMC Converting Enzyme
- Pro-Opiocortin Converting Protease
- Converting Protease, Pro-Opiocortin
- Pro Opiocortin Converting Protease
- Proopiomelanocortin Convertase
- Convertase, Proopiomelanocortin
- POMC Convertase
- Convertase, POMC
- Pro-Opiocortin Converting Enzyme
- Converting Enzyme, Pro-Opiocortin
- Pro Opiocortin Converting Enzyme
|
Below are MeSH descriptors whose meaning is more general than "Proprotein Convertases".
Below are MeSH descriptors whose meaning is more specific than "Proprotein Convertases".
This graph shows the total number of publications written about "Proprotein Convertases" by people in this website by year, and whether "Proprotein Convertases" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2005 | 0 | 1 | 1 | | 2008 | 1 | 0 | 1 | | 2010 | 1 | 0 | 1 | | 2011 | 0 | 1 | 1 | | 2013 | 1 | 0 | 1 | | 2014 | 1 | 1 | 2 | | 2016 | 0 | 1 | 1 | | 2023 | 1 | 1 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Proprotein Convertases" by people in Profiles.
-
Yang IV. Proprotein Convertase Subtilisin/Kexin Type 6: A Risk Factor for Survival in Pulmonary Fibrosis? Am J Respir Crit Care Med. 2023 06 01; 207(11):1421-1422.
-
Canonico ME, Hess CN, Cannon CP. In-Hospital Use of PCSK9 Inhibitors in the Post ACS Patient: What Does the Evidence Show? Curr Atheroscler Rep. 2023 07; 25(7):381-389.
-
Darlington TM, McCarthy RD, Cox RJ, Miyamoto-Ditmon J, Gallego X, Ehringer MA. Voluntary wheel running reduces voluntary consumption of ethanol in mice: identification of candidate genes through striatal gene expression profiling. Genes Brain Behav. 2016 06; 15(5):474-90.
-
Chait A, Eckel RH. Lipids, Lipoproteins, and Cardiovascular Disease: Clinical Pharmacology Now and in the Future. J Clin Endocrinol Metab. 2016 Mar; 101(3):804-14.
-
Everett BM, Smith RJ, Hiatt WR. Reducing LDL with PCSK9 Inhibitors--The Clinical Benefit of Lipid Drugs. N Engl J Med. 2015 Oct 22; 373(17):1588-91.
-
Schwartz GG, Bessac L, Berdan LG, Bhatt DL, Bittner V, Diaz R, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Mahaffey KW, Moryusef A, Pordy R, Roe MT, Rorick T, Sasiela WJ, Shirodaria C, Szarek M, Tamby JF, Tricoci P, White H, Zeiher A, Steg PG. Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial. Am Heart J. 2014 Nov; 168(5):682-9.
-
Lange LA, Hu Y, Zhang H, Xue C, Schmidt EM, Tang ZZ, Bizon C, Lange EM, Smith JD, Turner EH, Jun G, Kang HM, Peloso G, Auer P, Li KP, Flannick J, Zhang J, Fuchsberger C, Gaulton K, Lindgren C, Locke A, Manning A, Sim X, Rivas MA, Holmen OL, Gottesman O, Lu Y, Ruderfer D, Stahl EA, Duan Q, Li Y, Durda P, Jiao S, Isaacs A, Hofman A, Bis JC, Correa A, Griswold ME, Jakobsdottir J, Smith AV, Schreiner PJ, Feitosa MF, Zhang Q, Huffman JE, Crosby J, Wassel CL, Do R, Franceschini N, Martin LW, Robinson JG, Assimes TL, Crosslin DR, Rosenthal EA, Tsai M, Rieder MJ, Farlow DN, Folsom AR, Lumley T, Fox ER, Carlson CS, Peters U, Jackson RD, van Duijn CM, Uitterlinden AG, Levy D, Rotter JI, Taylor HA, Gudnason V, Siscovick DS, Fornage M, Borecki IB, Hayward C, Rudan I, Chen YE, Bottinger EP, Loos RJ, S?trom P, Hveem K, Boehnke M, Groop L, McCarthy M, Meitinger T, Ballantyne CM, Gabriel SB, O'Donnell CJ, Post WS, North KE, Reiner AP, Boerwinkle E, Psaty BM, Altshuler D, Kathiresan S, Lin DY, Jarvik GP, Cupples LA, Kooperberg C, Wilson JG, Nickerson DA, Abecasis GR, Rich SS, Tracy RP, Willer CJ. Whole-exome sequencing identifies rare and low-frequency coding variants associated with LDL cholesterol. Am J Hum Genet. 2014 Feb 06; 94(2):233-45.
-
Do RQ, Vogel RA, Schwartz GG. PCSK9 Inhibitors: potential in cardiovascular therapeutics. Curr Cardiol Rep. 2013 Mar; 15(3):345.
-
Goldberg AC, Hopkins PN, Toth PP, Ballantyne CM, Rader DJ, Robinson JG, Daniels SR, Gidding SS, de Ferranti SD, Ito MK, McGowan MP, Moriarty PM, Cromwell WC, Ross JL, Ziajka PE. Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol. 2011 May-Jun; 5(3):133-140.
-
Donovan EE, Pelanda R, Torres RM. S1P3 confers differential S1P-induced migration by autoreactive and non-autoreactive immature B cells and is required for normal B-cell development. Eur J Immunol. 2010 Mar; 40(3):688-98.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|